Literature DB >> 32144419

Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals.

Bin Wang1,2, Mian Li1,2, Zhiyun Zhao1,2, Shuangyuan Wang1,2, Jieli Lu1,2, Yuhong Chen1,2, Min Xu1,2, Weiqing Wang1,2, Guang Ning1,2, Yufang Bi1,2, Tiange Wang1,2, Yu Xu1,2.   

Abstract

CONTEXT: Type 2 diabetes (T2D) is closely associated with nonalcoholic fatty liver disease (NAFLD); however, evidence regarding the link between blood glucose, especially below the threshold for T2D, and NAFLD is scarce.
OBJECTIVE: The objective of this work is to examine the associations of fasting glucose, oral glucose tolerance test (OGTT) 2-hour glucose, and hemoglobin A1c (HbA1c), and changes in these measures with development and resolution of NAFLD in nondiabetic individuals.
METHODS: This longitudinal cohort study comprised 4273 Chinese adults age 40 years or older and free of baseline T2D from 2010 to 2015. Blood sampling was performed during the OGTT test. NAFLD was ascertained by hepatic ultrasonography. Risk ratios (RRs) were calculated using modified Poisson regression models.
RESULTS: During a mean 4.4 years of follow-up, NAFLD occurred in 573 (17.9%) of the 3209 participants without baseline NAFLD and resolved in 304 (28.6%) of the 1064 participants with baseline NAFLD. OGTT 2-h glucose was positively associated with NAFLD incidence (RR per 1-SD increase: 1.16, 95% CI: 1.08-1.25), whereas fasting (RR: 0.86, 95% CI: 0.78-0.94) and 2-hour glucose (RR: 0.85, 95% CI: 0.77-0.93) were inversely associated with resolution of NAFLD. Glycemic deterioration conferred increased risk of developing NAFLD and decreased likelihood of resolution of NAFLD than maintaining normal glycemic regulation (NGR). The strongest associations were observed for individuals who developed T2D. Meanwhile, baseline or incident NAFLD significantly increased the risk of deterioration in glucose metabolism.
CONCLUSIONS: Increased glycemic levels within the nondiabetic range, as well as progression from NGR to T2D or prediabetes, were adversely associated with development and improvement of NAFLD. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  blood glucose; diabetes; nonalcoholic fatty liver disease; prediabetes

Mesh:

Substances:

Year:  2020        PMID: 32144419     DOI: 10.1210/clinem/dgaa112

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes.

Authors:  Yilian Xie; Weiliang Kong; Xuepeng Wang; Zhouxiao Wu
Journal:  BMC Endocr Disord       Date:  2022-08-31       Impact factor: 3.263

2.  Nonalcoholic fatty liver disease in relation to the remission and progression along the glycemic continuum.

Authors:  Zhuojun Xin; Jiaojiao Huang; Qiuyu Cao; Jialu Wang; Ruixin He; Tianzhichao Hou; Yi Ding; Jieli Lu; Min Xu; Tiange Wang; Zhiyun Zhao; Weiqing Wang; Guang Ning; Yufang Bi; Yu Xu; Mian Li
Journal:  J Diabetes       Date:  2022-09       Impact factor: 4.530

3.  Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity.

Authors:  Domenico Corica; Giorgia Pepe; Tommaso Aversa; Monica Currò; Selenia Curatola; Alessandra Li Pomi; Angela Alibrandi; Riccardo Ientile; Malgorzata Wasniewska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-06       Impact factor: 5.555

4.  Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Andrea D Coviello; Manal F Abdelmalek; Anastasia-Stefania Alexopoulos; Matthew J Crowley; Ying Wang; Cynthia A Moylan; Cynthia D Guy; Ricardo Henao; Dawn L Piercy; Keri A Seymour; Ranjan Sudan; Dana D Portenier; Anna Mae Diehl
Journal:  Hepatology       Date:  2021-06-02       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.